Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

Viralgen and Axovia Therapeutics are joining forces to advance the development and manufacture of an AAV9-based inv ...

Magdalena aiming to submit Investigational ... of-concept (POC) human studies in 12-24 months - a huge time and cost savings which also, based on the history of human medicinal use of the plants ...

Co., Inc. (NYSE:MRK), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on ...

Chief Communications and Public Affairs Officer Cristal N. Downing recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On February 6, 2025, Downing ...

According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...